RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:WowThe numbers haven't even been testing yet. 1000's of tests per day and revenue from their main product to be considered a buyout. Google liquid biopsy companies and stage zero is a dark horse. I'll give that, a sneak attack, you can't defend what you don't see. Maybe two years of revenues would be the time to consider a buyout. Not likely any time soon. But hey liquid biopsy companies are earning 35 time p/e right now. So that is something to shoot for the first year out. Rookie contract time.
Nailbiter1 wrote: ompong12 wrote: StockscoutX wrote: I get the feeling that an early meeting could indicate a very important decision the shareholders must take.
i Vote for the BUY OUT.....take over is the KEY
Way ahead of yourself junior. Wanting a quick exit to satisfy a perpetual sweet tooth?
Premature e-sellulation happens to many.
If you believe in this tech's full potential, you'd wait for max results on multiple disease diagnostics.
I vote NAY for a premature buyout.
Roll out and expand.